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favor of DES implantation (OR 0.79, 95% CI 0.63 to 0.99, chi2 1.07, p0.04,
I2 0%).
Conclusions: Our study confirmed the cerebral vascular benefits of PCI by
significantly reducing CVA risks, and the composite outcome was better in
patients undergoing PCI with drug-eluting stent despite a higher repeat revascu-
larization rate. It poses imperative demands for future prospective randomized
studies to define the optimal strategy in patients with diabetes and left main and/or
multivessel disease.
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Background: The aim of this study is to compare the one year clinical outcomes in
patients with chronic total occlusion (CTO) lesion between diabetic and non-diabetic.
Methods: A total 3890 patients (Age; 62.99  11.04, Men; 74.1 %) with chronic total
occlusion were analyzed. The patients were divided into a diabetic group (n  2,579
patients) and a non-diabetic group (n 1,401 patients).We evaluated the one year clinical
outcomes including target lesion revascularization (TLR) and major adverse cardiac
events (MACEs) between the two groups.
Results: One year after PCI, 319 All-MACEs were developed. TLR and All-MACEs was
higher in diabetic group compared with that in non-diabetic group (respectively, 6.3 % vs.
8.9 %, p  0.022 and 12.2 % vs. 15.1%, p  0.047). In multivariate analysis, diabetic
mellitus was an independent predictor for one year TLR (OR; 1.414, p0.036) and
All-MACEs (OR; 1.743, p0.018).




OR ratio for 12-
month All-MACEs p
Age 0.999 (0.984-1.014) 0.887 0.993 (0.969-1.016) 0.948
Male 0.849 (0.591-1.220) 0.377 1.020 (0.564-1.843) 0.536
PCI Hx 0.916 (0.633-1.325) 0.641 0.859 (0.463-1.595) 0.631
HTN 1.012 (0.719-1.424) 0.946 0.839 (0.518-1.357) 0.474
CHF 1.836 (1.070-3.153) 0.028 1.050 (0.407-2.708) 0.920
DM 1.414 (1.023-1.953) 0.036 1.743 (1.102-2.758) 0.018
Conclusions: This study identified diabetic mellitus as an independent risk factor for one
year TLR and All-MACEs in patients with CTO lesion.
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Background: Biodegradable polymer drug eluting stents improve safety and efficacy when
compared to durable polymer drug eluting stents, but this may not be true in diabetic patients.
Methods: This prospective single center registry compared primary efficacy composite
end point of cardiac death, myocardial infarction and clinically indicated target-lesion
revascularization, primary safety end point defined as the rate of stent thrombosis and long
term survival in diabetic patients (pts) receiving biodegradable polymer Biolimus-Eluting
Stents (BES) or durable polymer Everolimus-Eluting Stents (EES).
Results: A total of 278 stents (133 BES and 145 EES) were implanted in 251 diabetic pts
(179 males, 6% type 1 diabetes) aged 6610 years who presented with Acute Coronary
Syndrome (n64, 25%) or stable angina (n133, 53%). Multiple vessel disease was present
in 63% pts. Vessels treated were 114 Left Anterior Descending, 76 Circumflex, 77 Right
Coronary, 8 Left Main. Dual antiplatelet therapy was given for at least 12 months. Baseline
clinical characteristics, cardiovascular risk factors, lesions location and classification were not
statistically significantly different in the two groups receiving BES (Group 1, n118 pts) and
EES (Group 2, n133 pts). At the end of the follow-up-period [median 19 (0-44) months], no
statistically significant difference was found in the occurrence of the primary efficacy
composite end point in the 2 groups (8.5% in Group 1 versus (vs) 12.3% in Group 2, p0.65),
nor in the occurrence of the primary safety end point (1.7% in Group 1 vs 1.8% in Group 2,
p0.22). There was no difference in cardiac death (2.5% in Group 1 vs 2.6% in Group 2,
p0.64), myocardial infarction (4.1% in Group 1 vs 3.6% in Group 2, p0.42), target vessel
revascularization (10% in Group 1 vs 11% in Group 2, p0.95) and target lesion revascular-
ization (7% in Group 1 vs 8% in Group 2, p0.82). The overall survival (Kaplan Meyer) was
not significantly different in both groups (log rank0.53).
Conclusions: In conclusion, clinical efficacy and safety of new generation biodegradable
polymer BES and durable polymer EES are similar in diabetic pts confirming that diabetes
is an entity in terms of coronary artery disease.
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